GlaxoSmithKline (GSK.L) set out a roadmap for a potential 2016 flotation of its HIV medicines business on Wednesday as it hired three leading banks to advise on what would be the drug industry’s largest ever initial public share sale.
Chief Executive Andrew Witty said his company would take the next two to three months to analyze the pros and cons of an initial public offering (IPO), as well as deciding how much of ViiV to sell and where to list the shares.
{iframe}http://in.reuters.com/article/2015/02/04/us-gsk-viiv-ipo-idINKBN0L80ZS20150204{/iframe}